Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloid leukemia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 195.00 | |
2 mg | In stock | $ 293.00 | |
5 mg | In stock | $ 449.00 | |
10 mg | In stock | $ 659.00 | |
25 mg | In stock | $ 987.00 | |
50 mg | In stock | $ 1,390.00 | |
100 mg | In stock | $ 1,880.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 591.00 |
Description | CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloid leukemia. |
Targets&IC50 | Abl (V299L):(kd)228 nM , Abl kinase:7.9 nM , BCR-ABL:27.9 nM |
In vitro | CHMFL-ABL-039 (0.01-3 μM; 4 hours) can dose-dependently inhibit the ABL Y245 phosphorylation and the subsequent downstream signaling mediators. CHMFL-ABL-039 (0-10 μM; 72 hours) is 6-10 fold more sensitive than Imatinib to BCR-ABL driven cancer cell lines, and BCR-ABL independent cell lines display a great selectivity window comparing to BCR-ABL driven cancer cell lines[1]. |
In vivo | CHMFL-ABL-039 (0.01-3 μM; 4 hours) can dose-dependently inhibit the ABL Y245 phosphorylation and the subsequent downstream signaling mediators. CHMFL-ABL-039 (0-10 μM; 72 hours) is 6-10 fold more sensitive than Imatinib to BCR-ABL drove cancer cell lines, and BCR-ABL independent cell lines display a great selectivity window comparing to BCR-ABL drove cancer cell lines[1]. |
Molecular Weight | 594.63 |
Formula | C31H33F3N6O3 |
CAS No. | 2304344-56-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (92.49 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CHMFL-ABL-039 2304344-56-5 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl CHMFL-ABL039 CHMFL-ABL 039 CHMFLABL039 CHMFL ABL 039 inhibitor inhibit